World's Best Scientists 2026 revealed!
Jacob Schachter

Jacob Schachter

D-Index & Metrics

Biology and Biochemistry

D-Index
69
Citations
32993
World Ranking
7222
National Ranking
63

Jacob Schachter publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Jacob Schachter sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 413 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 848 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 949 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 840 scientists 207–216 publications: 733 scientists 217–226 publications: 708 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 417 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 196 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 59 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 390 publications — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Jacob Schachter D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Jacob Schachter sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 316 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 899 scientists 52–53 D-Index: 1,025 scientists 54–55 D-Index: 1,149 scientists 56–57 D-Index: 1,235 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,162 scientists 62–63 D-Index: 1,130 scientists 64–65 D-Index: 1,031 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 714 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 71 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 69 D-Index — 63rd percentile

63% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Jacob Schachter is affiliated with Sheba Medical Center in Israel. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a strong focus on subfields such as Oncology, Molecular Biology, Immunology, Epidemiology, and Electrical and Electronic Engineering.

The scientist's work covers several main topics, including:

  • CAR-T cell therapy research
  • Cancer Immunotherapy and Biomarkers
  • Melanoma and MAPK Pathways
  • Immunotherapy and Immune Responses
  • Cutaneous Melanoma Detection and Management
  • Nonmelanoma Skin Cancer Studies
  • Immune Cell Function and Interaction

Jacob Schachter has contributed to a variety of research papers in prominent journals. Recent publications include:

  • Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients, 2020, Science
  • Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma, 2020, New England Journal of Medicine
  • Identification of bacteria-derived HLA-bound peptides in melanoma, 2021, Nature
  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial, 2021, The Lancet Oncology
  • Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629), 2020, Journal of Clinical Oncology

Frequent coauthors of Jacob Schachter include:

  • Georgina V. Long
  • Caroline Robert
  • Jean-Jacques Grob
  • Laurent Mortier
  • Ana Arance

The scientist often publishes in venues such as:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancer Research
  • The Lancet Oncology
  • Journal for ImmunoTherapy of Cancer

Best Publications

  • Pembrolizumab versus Ipilimumab in Advanced Melanoma

    Caroline Robert;Caroline Robert;Caroline Robert;Jacob Schachter;Georgina V. Long;Ana Arance

  • Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

    Caroline Robert;Boguslawa Karaszewska;Jacob Schachter;Piotr Rutkowski

  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Antoni Ribas;Igor Puzanov;Reinhard Dummer;Dirk Schadendorf

  • Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

    Erez N. Baruch;Erez N. Baruch;Ilan Youngster;Guy Ben-Betzalel;Rona Ortenberg

  • Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

    G. V. Long;A. Hauschild;M. Santinami;V. Atkinson

  • Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

    Caroline Robert;Jean J Grob;Daniil Stroyakovskiy;Boguslawa Karaszewska

  • Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

    Antoni Ribas;Richard Kefford;Margaret A. Marshall;Cornelis J.A. Punt

  • Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients

    Michal J. Besser;Ronnie Shapira-Frommer;Avraham J. Treves;Dov Zippel

  • Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer : a European organization for research and treatment of cancer randomized study with cross-over

    Robert Paridaens;L. Biganzoli;P. Bruning;J.G.M. Klijn

  • Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies

    Michal J. Besser;Ronnie Shapira-Frommer;Orit Itzhaki;Avraham J. Treves

  • Identification of bacteria-derived HLA-bound peptides in melanoma

    Shelly Kalaora;Adi Nagler;Deborah Nejman;Michal Alon

  • Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

    Reinhard Dummer;Axel Hauschild;Mario Santinami;Victoria Atkinson

  • Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

    Paolo Antonio Ascierto;Pier Francesco Ferrucci;Rosalie Fisher;Michele Del Vecchio

  • Vemurafenib in patients with BRAF V600 mutated metastatic melanoma: an open-label, multicentre, safety study

    James Larkin;Michele Del Vecchio;Paolo A Ascierto;Ivana Krajsova

  • Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence

    Michal Harel;Rona Ortenberg;Rona Ortenberg;Siva Karthik Varanasi;Kailash Chandra Mangalhara

  • Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

    Mario Sznol;Pier Francesco Ferrucci;David Hogg;Michael B Atkins

  • Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial

    Jean Jacques Grob;Mayur M Amonkar;Boguslawa Karaszewska;Jacob Schachter

  • Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma

    Steven J. O'Day;Alexander M.M. Eggermont;Vanna Chiarion-Sileni;Richard Kefford

  • Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma

    Axel Hauschild;Reinhard Dummer;Dirk Schadendorf;Dirk Schadendorf;Mario Santinami

  • Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)

    Richard D. Carvajal;Sophie Piperno-Neumann;Ellen Kapiteijn;Paul B. Chapman

Frequent Co-Authors

Gal Markel
Gal Markel Tel Aviv University
Georgina V. Long
Georgina V. Long University of Sydney
Caroline Robert
Caroline Robert University of Paris-Saclay
Antoni Ribas
Antoni Ribas University of California, Los Angeles
James Larkin
James Larkin Royal Marsden NHS Foundation Trust
Axel Hauschild
Axel Hauschild Kiel University
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Jean-Jacques Grob
Jean-Jacques Grob Aix-Marseille University
Reinhard Dummer
Reinhard Dummer University of Zurich
Matteo S. Carlino
Matteo S. Carlino University of Sydney

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Biology and Biochemistry can open up a wide range of career opportunities in healthcare, research, and industry. For those interested in clinical nutrition or wellness, pursuing the fastest nutrition degree may provide a quicker pathway into the workforce, allowing for a more flexible study schedule and faster completion rates.

Advancing into leadership or administrative roles within healthcare is also a popular option. Students who want to expand their business skills may consider the healthcare mba cost to identify programs that balance affordability with high ROI.

Healthcare informatics and medical coding offer alternative career pathways that combine science with technology. Understanding the distinction between a certified coding specialist (ccs) and other credentials is important; read more about certified coding specialist (ccs) qualifications, costs, and salary prospects.

For those who enjoy detail-oriented work and data management, a career in medical coding could be ideal. Discover the necessary steps to enter the field, along with medical.coder salary trends and growth potential in this expanding sector.

Best Scientists Citing Jacob Schachter

Trending Scientists

Recently Published Articles